AlFawaz Ibrahim, Ahmed Basheer, Ali Afshan, Ayas Mouhab, AlKofide Amani, Habib Zakaria, Siddiqui Khawar
Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Surgery King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Int J Pediatr Adolesc Med. 2021 Mar;8(1):39-43. doi: 10.1016/j.ijpam.2020.11.001. Epub 2020 Nov 13.
Many studies have demonstrated that outcome in patients with hepatoblastoma is determined by tumor resectability and the presence or absence of metastatic disease.
To evaluate and disseminate information on diagnosis, treatment, and outcome of hepatoblastoma patients at a tertiary care hospital in Saudi Arabia.
Twenty-four pediatric patients with hepatoblastoma were treated at our institution between January 2005 and December 2012. The majority of our patients were stage III and above, while one-third of them presented with metastatic disease. Four (16.7%) had vascular invasion. Two-thirds of our patients (n = 16, 66.7%) had alpha-fetoprotein (AFP) level above 100,000 ng/mL. Twenty-one patients underwent surgery; two had upfront surgery before getting any chemotherapy, and 15 had surgery on schedule after pre-operative chemotherapy. Four patients had delayed surgery as the tumor was not resectable and received extra cycles of chemotherapy. Chemotherapy regimens used were based on SIOPEL study protocols until 2011 and Children's Oncology Group (COG) protocol from 2012 onwards. Relapse, progressive disease, or death from any cause were defined as events.
Five-year overall survival (OS) of the cohort over a median follow-up time of 56.1 months was 70.6% ± 9.4% with seven (29.2%) events of mortality. No significant difference was found for age at diagnosis (less than 2 years vs. more), stage of disease, AFP levels (less than 100,000 vs. more), vascular invasion, or presence of metastatic disease at presentation in terms of OS. However, children receiving upfront or scheduled as-per-protocol surgery fared better than those who had delayed surgery (as the tumor was not resectable and they received extra cycles of chemotherapy) or did not undergo any surgery ( .001).
Favorable survival outcome could be achieved with complete tumor excision and adjuvant chemotherapy. Inability to perform surgical excision was the single most important predictor of mortality in our patients.
许多研究表明,肝母细胞瘤患者的预后取决于肿瘤的可切除性以及是否存在转移性疾病。
评估并传播沙特阿拉伯一家三级护理医院肝母细胞瘤患者的诊断、治疗及预后信息。
2005年1月至2012年12月期间,我院共治疗了24例小儿肝母细胞瘤患者。大多数患者为III期及以上,其中三分之一伴有转移性疾病。4例(16.7%)有血管侵犯。三分之二的患者(n = 16,66.7%)甲胎蛋白(AFP)水平高于100,000 ng/mL。21例患者接受了手术;2例在接受任何化疗前先行手术,15例在术前化疗后按计划进行手术。4例患者因肿瘤无法切除而延迟手术,并接受了额外疗程的化疗。2011年前使用的化疗方案基于SIOPEL研究方案,2012年起采用儿童肿瘤学组(COG)方案。复发、疾病进展或任何原因导致死亡均被定义为事件。
该队列患者中位随访时间为56.1个月,5年总生存率(OS)为70.6% ± 9.4%;7例(29.2%)死亡。在OS方面,诊断时的年龄(小于2岁与大于2岁)、疾病分期、AFP水平(小于100,000与大于100,000)、血管侵犯或就诊时是否存在转移性疾病之间未发现显著差异。然而,接受先行或按方案计划手术的儿童比延迟手术(因肿瘤无法切除而接受额外疗程化疗)或未接受任何手术的儿童预后更好(P <.001)。
通过完整切除肿瘤和辅助化疗可实现良好的生存预后。无法进行手术切除是我们患者死亡的唯一最重要预测因素。